<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875367</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2012-07</org_study_id>
    <secondary_id>2012-004928-38</secondary_id>
    <nct_id>NCT01875367</nct_id>
  </id_info>
  <brief_title>Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer</brief_title>
  <acronym>ChangHER-SC</acronym>
  <official_title>Phase III Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous (IV) Administration in HER2 Positive Advanced Breast Cancer Who Have Received IV Trastuzumab at Least 4 Months and Without Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national&#xD;
      designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of&#xD;
      trastuzumab, and within the SC by the administration through the vial or device&#xD;
      self-administration in patients with disseminated breast cancer HER2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 195 patients will be included to receive subcutaneous trastuzumab a fixed dose&#xD;
      of 600 mg every 3 weeks for 4 cycles (2 administered from the injection of a vial with a&#xD;
      syringe and 2 with the injection device). Following administration of these four cycles, the&#xD;
      patient will decide whether or not to continue with the subcutaneous formulation of&#xD;
      trastuzumab every 3 weeks until progression (out of the study). Since the randomization in&#xD;
      the study until the start with subcutaneous trastuzumab, patients will receive a treatment&#xD;
      cycle of intravenous trastuzumab as usual.&#xD;
&#xD;
      Main objective: Proportion of patients indicate a preference for the use of subcutaneous vs&#xD;
      intravenous trastuzumab.&#xD;
&#xD;
      This principal primary objective will be analyzed with the answers to questionnaire of&#xD;
      experiences and preferences of the patients (Principal endpoint) The duration of the study&#xD;
      has been estimated after 34 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2013</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients, from the randomization and before starting subcutaneous trastuzumab (SC-t), received an additional intravenous (IV-t) cycle. After receiving this cycle, patients started the treatment with the study medication, SC-t at a fixed dose of 600 mg every 3 weeks (+3 days) for 4 cycles (2 administered from the injection of a vial in a syringe and 2 with the single-use injection device [SID]), being randomized 1:1 in two arms of treatment without washout period:&#xD;
Arm A (1 cycle of IV-t followed by 2 cycles of SC-t with vial followed by 2 cycles of SC-t with SID)&#xD;
Arm B (1 cycle of IV-t followed by 2 cycles of SC-t with SID followed by 2 cycles of SC-t with vial)&#xD;
This is not a cross-over study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Medical Staff With Intravenous vs. Subcutaneous Preference</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff.&#xD;
Health care professionals were not considered enrolled, but did contribute to this assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Medical Staff Subcutaneous Device vs. Vial Preference</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Time in Healthcare Unit and Sitting in Chair/Bed</measure>
    <time_frame>An average of 4 months</time_frame>
    <description>Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit.&#xD;
Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Experienced Adverse Events (AE)</measure>
    <time_frame>Through study treatment, an average of 12 weeks</time_frame>
    <description>Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: T-IV + T-SC vial + T-SC device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: T-IV + T-SC device + T-SC vial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab Injectable Solution</intervention_name>
    <description>Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.</description>
    <arm_group_label>Arm A: T-IV + T-SC vial + T-SC device</arm_group_label>
    <arm_group_label>Arm B: T-IV + T-SC device + T-SC vial</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab Injectable Product</intervention_name>
    <description>Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles</description>
    <arm_group_label>Arm A: T-IV + T-SC vial + T-SC device</arm_group_label>
    <arm_group_label>Arm B: T-IV + T-SC device + T-SC vial</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab Injection</intervention_name>
    <description>Powder for concentrate for solution for infusion. 1 cycle</description>
    <arm_group_label>Arm A: T-IV + T-SC vial + T-SC device</arm_group_label>
    <arm_group_label>Arm B: T-IV + T-SC device + T-SC vial</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman, 18 years old or upper.&#xD;
&#xD;
          -  Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER&#xD;
             2) positive histologically confirmed. The criteria for positivity HER 2 are:&#xD;
&#xD;
               1. immuno-histochemistry (IHC) 3+ (&gt;10% of tumor cells with complete and intense&#xD;
                  membrane staining)&#xD;
&#xD;
               2. IHC 2+ with fluorescent in situ hybridization (FISH) / Chromogenic in situ&#xD;
                  hybridization (CISH) / silver-enhanced in situ hybridization (SISH) + for HER 2&#xD;
                  amplification (*)&#xD;
&#xD;
               3. FISH / CISH / SISH + for HER 2 amplification (*) (*) Defined as the ratio of&#xD;
                  copies of HER 2/neu and copies of centromere of chromosome 17 (CEP17)&gt; 2.2, or a&#xD;
                  number of copies of HER 2/neu&gt; 6, as per local laboratory criteria.&#xD;
&#xD;
          -  Patient receiving trastuzumab with or without chemotherapy or hormonal therapy for at&#xD;
             least 4 months.&#xD;
&#xD;
          -  No evidence of disease progression (clinical and / or radiological) for at least 4&#xD;
             months before inclusion in the study and with a life expectancy of at least 3 months.&#xD;
&#xD;
          -  Adequate performance status: Eastern Cooperative Oncology Group (ECOG) &lt;2.&#xD;
&#xD;
          -  Adequate bone marrow function, liver and kidney&#xD;
&#xD;
          -  Proper cardiac function (LVEF within normal limits the center, measured by&#xD;
             echocardiography or MUGA).&#xD;
&#xD;
          -  The patient must have been informed of the study and must sign and date informed&#xD;
             consent document for entry into the trial.&#xD;
&#xD;
          -  The patient must be willing and able to comply with study procedures and be available&#xD;
             to answer the study questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with no advanced breast cancer.&#xD;
&#xD;
          -  Breast cancer patients with tumors HER 2-negative.&#xD;
&#xD;
          -  The patient has another active malignancy other than breast adenocarcinoma; are&#xD;
             excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia.&#xD;
             Patients with a history of malignancy, if they bear&gt; 5 years without evidence of&#xD;
             disease could be included.&#xD;
&#xD;
          -  The patient has uncontrolled brain metastases.&#xD;
&#xD;
          -  Concomitant administration, or in the 4 weeks prior to study entry, of other&#xD;
             experimental treatment.&#xD;
&#xD;
          -  Known hypersensitivity to trastuzumab or to any of its components.&#xD;
&#xD;
          -  Patients with severe dyspnea at rest or requiring supplemental oxygen.&#xD;
&#xD;
          -  Heart disease or serious medical pathological prevent trastuzumab administration:&#xD;
             documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias&#xD;
             uncontrolled angina requiring medication, clinically significant valvular disease,&#xD;
             history of myocardial infarction or evidence of transmural infarction on ECG or&#xD;
             hypertension poorly controlled.&#xD;
&#xD;
          -  Presence of any concomitant serious systemic disease that is incompatible with the&#xD;
             study (at the discretion of the investigator).&#xD;
&#xD;
          -  The patient is pregnant or lactating. Women of childbearing potential should undergo&#xD;
             pregnancy testing blood or urine within 14 days prior to inclusion as institutional&#xD;
             rules and use a non-hormonal contraceptive suitable: intrauterine device, barrier&#xD;
             method (condom or diaphragm) also used in conjunction with spermicidal cream, total&#xD;
             abstinence or surgical sterilization, during treatment with the study drugs and for 6&#xD;
             months following the end of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan Despí Moises Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Puerto de Plasencia</name>
      <address>
        <city>Plasencia</city>
        <state>Cáceres</state>
        <zip>10600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manacor</name>
      <address>
        <city>Manacor</city>
        <state>Illes Balears</state>
        <zip>07500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28924</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univesitario Quirón Madrid</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Sonsoles</name>
      <address>
        <city>Ávila</city>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Sponsor's web</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <results_first_submitted>October 9, 2020</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2021</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subcutaneous trastuzumab</keyword>
  <keyword>Intravenous trastuzumab</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible patients, from the randomization and before starting subcutaneous trastuzumab (SC-t), received an additional intravenous (IV-t) cycle. After receiving this cycle, patients started the treatment with the study medication, SC-t at a fixed dose of 600 mg every 3 weeks (+3 days) for 4 cycles (2 administered from the injection of a vial in a syringe and 2 with the single-use injection device [SID]), being randomized 1:1 in two arms of treatment without washout period.</recruitment_details>
      <pre_assignment_details>This is not a cross-over study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: T-IV + T-SC Vial + T-SC Device</title>
          <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: T-IV + T-SC Device + T-SC Vial</title>
          <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not complete at least 2 questionaries</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not receive study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: T-IV + T-SC Vial + T-SC Device</title>
          <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: T-IV + T-SC Device + T-SC Vial</title>
          <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="35" upper_limit="93"/>
                    <measurement group_id="B2" value="58" lower_limit="38" upper_limit="85"/>
                    <measurement group_id="B3" value="60" lower_limit="35" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arabian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Premenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Postmenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) performance status</title>
          <description>Measure Description: ECOG score runs from 0 to 5, with 0 denoting perfect health and 5 death.&#xD;
0 - Asymptomatic&#xD;
- Symptomatic but completely ambulatory&#xD;
- Symptomatic, &lt;50% in bed during the day&#xD;
- Symptomatic, &gt;50% in bed, but not bedbound&#xD;
- Bedbound&#xD;
- Death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ECOG 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECOG 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECOG 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estrogen Receptor</title>
          <description>A cancer is called hormonal receptor positive if it has receptors for progesterone or estrogen. This suggests that the cancer cells, like normal breast cells, may receive signals from progesterone or estrogen that could promote their growth.&#xD;
If the cancer is hormone-receptor-negative (no receptors are present), then hormonal therapy is unlikely to work.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Progesterone Receptor</title>
          <description>A cancer is called hormonal receptor positive if it has receptors for progesterone or estrogen. This suggests that the cancer cells, like normal breast cells, may receive signals from progesterone or estrogen that could promote their growth.&#xD;
If the cancer is hormone-receptor-negative (no receptors are present), then hormonal therapy is unlikely to work.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time with IV trastuzumab for metastasis at registration</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" lower_limit="0.35" upper_limit="13.67"/>
                    <measurement group_id="B2" value="1.78" lower_limit="0.34" upper_limit="14.05"/>
                    <measurement group_id="B3" value="1.8" lower_limit="0.34" upper_limit="14.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment/s combined with IV-trastuzumab at registration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Homonotherapy (HT)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chemotherapy (CT)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other anti-cancer therapy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other anti-cancer therapy+CT</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other anti-cancer therapy+HT</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other anti Human Epidermal growth factor Receptor 2 (HER-2) therapy at registration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pertuzumab</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lapatinib</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Administration route at registration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Intravenous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intramuscular</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subcutaneous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Oral</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metastases 1 at diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visceral metastases at registration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone metastases at registration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin/soft tissue/lymph nodes metastases at registration</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median of prior treatment lines at registration</title>
          <description>The greater number of lines previously received by a patient, the worst prognosis.</description>
          <units>Treatment lines</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="B3" value="1" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior treatment lines at registration</title>
          <description>The greater number of lines previously received by a patient, the worst prognosis.</description>
          <units>Treatment lines</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Lines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Lines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Lines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Lines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Lines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 Lines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference</title>
        <description>The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Patients were randomized 1:1 in 2 arms:&#xD;
Arm A: (1 cycle IV-t followed by 2 cycles SC-t with vial followed by 2 cycles SC-t with SID) Arm B: (1 cycle IV-t followed by 2 cycles SC-t with SID followed by 2 cycles SC-t with vial)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: T-IV + T-SC Vial + T-SC Device</title>
            <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: T-IV + T-SC Device + T-SC Vial</title>
            <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference</title>
          <description>The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.</description>
          <population>Patients were randomized 1:1 in 2 arms:&#xD;
Arm A: (1 cycle IV-t followed by 2 cycles SC-t with vial followed by 2 cycles SC-t with SID) Arm B: (1 cycle IV-t followed by 2 cycles SC-t with SID followed by 2 cycles SC-t with vial)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subcutaneous</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intravenous</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No preference</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference</title>
        <description>The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Patients were randomized 1:1 in 2 arms:&#xD;
Arm A: (1 cycle IV-t followed by 2 cycles SC-t with vial followed by 2 cycles SC-t with SID) Arm B: (1 cycle IV-t followed by 2 cycles SC-t with SID followed by 2 cycles SC-t with vial) It has been analysed in patients from Intention To Treat (ITT) population which have completed questionnaire nº 3 (Arm A 72 patients and Arm B 80 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: T-IV + T-SC Vial + T-SC Device</title>
            <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: T-IV + T-SC Device + T-SC Vial</title>
            <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference</title>
          <description>The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.</description>
          <population>Patients were randomized 1:1 in 2 arms:&#xD;
Arm A: (1 cycle IV-t followed by 2 cycles SC-t with vial followed by 2 cycles SC-t with SID) Arm B: (1 cycle IV-t followed by 2 cycles SC-t with SID followed by 2 cycles SC-t with vial) It has been analysed in patients from Intention To Treat (ITT) population which have completed questionnaire nº 3 (Arm A 72 patients and Arm B 80 patients).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Device</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Vial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No preference</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not answered</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Medical Staff With Intravenous vs. Subcutaneous Preference</title>
        <description>The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff.&#xD;
Health care professionals were not considered enrolled, but did contribute to this assessment.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Questionnaires were given to the health care professionals of both arms. Information has been analyzed per administration type, not per arm.&#xD;
39 health care professional satisfaction questionnaires were completed. Health care professionals were not considered enrolled, but did contribute to this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms</title>
            <description>Questionnaires were given to the health care professionals of both arms. There have been completed 39 health care professional satisfaction questionnaires. Information not provided by arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Medical Staff With Intravenous vs. Subcutaneous Preference</title>
          <description>The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff.&#xD;
Health care professionals were not considered enrolled, but did contribute to this assessment.</description>
          <population>Questionnaires were given to the health care professionals of both arms. Information has been analyzed per administration type, not per arm.&#xD;
39 health care professional satisfaction questionnaires were completed. Health care professionals were not considered enrolled, but did contribute to this assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subcutaneous</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intravenous</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No differences</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not answered</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Medical Staff Subcutaneous Device vs. Vial Preference</title>
        <description>The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Questionnaires were given to the health care professionals of both arms. Information has been analyzed per administration type, not per arm.&#xD;
39 health care professional satisfaction questionnaires were completed. Health care professionals were not considered enrolled, but did contribute to this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms</title>
            <description>Questionnaires were given to the health care professionals of both arms. There have been completed 39 health care professional satisfaction questionnaires. Information not provided by arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Medical Staff Subcutaneous Device vs. Vial Preference</title>
          <description>The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.</description>
          <population>Questionnaires were given to the health care professionals of both arms. Information has been analyzed per administration type, not per arm.&#xD;
39 health care professional satisfaction questionnaires were completed. Health care professionals were not considered enrolled, but did contribute to this assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Preferred device</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Preferred vial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Preference</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Time in Healthcare Unit and Sitting in Chair/Bed</title>
        <description>Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit.&#xD;
Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.</description>
        <time_frame>An average of 4 months</time_frame>
        <population>This analysis was considered from 87 patients of the 166 patients included into the study, on who information of observed tasks were collected. 217 observations were made from these patients: 74 about IV-t administration process, 75 about SC-SID administration process, 68 about SC-Vial administration process.</population>
        <group_list>
          <group group_id="O1">
            <title>Both Arms: Intravenous-Trastuzumab (IV-t)</title>
            <description>Patients from both arms (A and B) who received Intravenous-Trastuzumab as per clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>Both Arms: Subcutaneous-Trastuzumab Vial (SC-t Vial)</title>
            <description>Patients from both arms (A and B) who received Subcutaneous (SC) injection vial.</description>
          </group>
          <group group_id="O3">
            <title>Boths Arms: Subcutaneous-Trastuzumab Device (SC-t SID)</title>
            <description>Patients from both arms (A and B) who received Single injection device</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Time in Healthcare Unit and Sitting in Chair/Bed</title>
          <description>Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit.&#xD;
Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.</description>
          <population>This analysis was considered from 87 patients of the 166 patients included into the study, on who information of observed tasks were collected. 217 observations were made from these patients: 74 about IV-t administration process, 75 about SC-SID administration process, 68 about SC-Vial administration process.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Observations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Observations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Healthcare unit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" spread="123.57"/>
                    <measurement group_id="O2" value="144.84" spread="121.99"/>
                    <measurement group_id="O3" value="122.9" spread="112.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting in the infusion/treatment chair/bed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.01" spread="56.34"/>
                    <measurement group_id="O2" value="31.6" spread="28.74"/>
                    <measurement group_id="O3" value="24.75" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Experienced Adverse Events (AE)</title>
        <description>Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.</description>
        <time_frame>Through study treatment, an average of 12 weeks</time_frame>
        <population>Safety Population included all patients randomized in the study who received at least one dose of treatment, and they were analyzed according to the actual treatment received (81 patients in arm A and 85 patients in arm B).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: T-IV + T-SC Vial + T-SC Device</title>
            <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: T-IV + T-SC Device + T-SC Vial</title>
            <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Experienced Adverse Events (AE)</title>
          <description>Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.</description>
          <population>Safety Population included all patients randomized in the study who received at least one dose of treatment, and they were analyzed according to the actual treatment received (81 patients in arm A and 85 patients in arm B).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study treatment, an average of 12 weeks</time_frame>
      <desc>AE were reported after Informed Consent Document (ICD) and before study drugs until approximately 30 days following the discontinuation of study treatment.&#xD;
AEs were recorded for each Arm group Arm A and Arm B, so information can not be provided separately per intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: T-IV + T-SC Vial + T-SC Device</title>
          <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: T-IV + T-SC Device + T-SC Vial</title>
          <description>Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Catheter related infection (Bacteriemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lack of strength in left leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Ostenecrosis produced by biphosphonates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nodule in left breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nodule in right breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Surgery for surgical castration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI-CTCAE 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hemoglobin increased</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>White blood cells decreased</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>White blood cells decreased</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nodule in left breast</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Voice alteration</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We do not have longterm follow-up data of the SC-t efficacy. Device SC-t SID has not been commercialized. All patients had already been treated with IV-t for at least 4 months without disease progression prior to the study entry.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Scientific Director / Medical Lead / Project Manager</name_or_title>
      <organization>Spanish Breast Cancer Research Group</organization>
      <phone>+34916592870</phone>
      <email>geicam@geicam.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

